Taysha Gene Therapies, Inc. (TSHA)
NASDAQ: TSHA · Real-Time Price · USD
1.930
+0.050 (2.66%)
At close: Mar 28, 2025, 4:00 PM
1.905
-0.025 (-1.28%)
After-hours: Mar 28, 2025, 7:56 PM EDT
Taysha Gene Therapies Market Cap
Taysha Gene Therapies has a market cap or net worth of $395.65 million as of March 28, 2025. Its market cap has decreased by -6.36% in one year.
Market Cap
395.65M
Enterprise Value
320.18M
1-Year Change
-6.36%
Ranking
Category
Stock Price
$1.93
Market Cap Chart
Since the IPO on September 24, 2020, Taysha Gene Therapies's market cap has decreased from $690.43M to $395.65M, a decrease of -42.69%. That is a compound annual growth rate of -11.61%.
Market Cap History
| Date | Market Cap | % Change |
|---|---|---|
| Mar 28, 2025 | 395.65M | 11.59% |
| Dec 31, 2024 | 354.55M | 7.14% |
| Dec 29, 2023 | 330.92M | 134.50% |
| Dec 30, 2022 | 141.12M | -68.52% |
| Dec 31, 2021 | 448.22M | -55.28% |
| Dec 31, 2020 | 1.00B | 45.15% |
Market Capitalization
Market capitalization, also called net worth, is the total value of all of a company's outstanding shares. It is calculated by multiplying the stock price by the number of shares outstanding.
Formula: Market Cap = Stock Price * Shares Outstanding
Full DefinitionRelated Stocks
| Company | Market Cap |
|---|---|
| Eli Lilly and Company | 736.07B |
| UnitedHealth Group | 473.63B |
| Johnson & Johnson | 394.66B |
| AbbVie | 362.46B |
| Novo Nordisk | 305.46B |
| Abbott Laboratories | 228.29B |
| Merck & Co. | 226.28B |
| AstraZeneca | 225.00B |